



Working to improve your health

3 May 2024

AFT Pharmaceuticals to announce full year results on Thursday May 23 2024

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release its full year FY2024, ended March 31 2024, results on Thursday May 23 2024. The release will be issued at around 09:00 am (NZT) on the NZX and ASX.

Following the release, management will present via webinar at 10:30 am (NZT). Presentation material will be available on the company's website [AFT](#), the NZX website [NZX](#) and the ASX website [ASX](#).

To participate in the upcoming earnings webinar, please pre-register with the provided link, below. Webinar details will be provided upon completion of your registration.

Registration Link: [AFT results presentation FY2024](#)

For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.

For more information:

Investors

Malcolm Tubby
CFO, AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232
Email: malcolm@aftpharm.com

Media

Richard Inder
The Project
Phone: 021 645 643
Email: richard@theproject.co.nz

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com